Group Psychotherapy in Narcolepsy Type 1
Effectiveness of Group Psychotherapy in Patients With Narcolepsy Type 1
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
St.Gallen, Switzerland, 9000
- Clinic for Psychosomatic Medicine, Cantonal Hospital St.Gallen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed narcolepsy type 1 according to AASM, examined by an experienced sleep physician including history, clinical examination, polysomnographic examination (PSG) with a multiple sleep latency test (MSLT), possibly also including determination of HLA DQB1 * 062 and orexin A / hypocretin 1
- Age between 18 and 65 years
- Signed informed consent
- Exclusion of other clinically relevant organic sleep disorders by means of polysomnography (AHI>10/h)
Exclusion Criteria:
- Presence of severe psychiatric comorbidity
- Other psychotherapy during the study period
- Change of medication used for narcolepsy therapy shortly before the start and during the study period including follow-up measurement. In this case, patients may still complete group therapy, but the data will not be included in the analysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention
Group psychotherapy
|
Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue (Severity)
Time Frame: Week 0-24
|
German version of the questionnaire "Fatigue Severity Scale" (FSS; Valko et al., 2008)
|
Week 0-24
|
|
Daytime sleepiness
Time Frame: Week 0, Week 6, Week 12, Week 24
|
German version of the questionnaire "Epworth Sleepiness Scale" (ESS; Johns, 1991)
|
Week 0, Week 6, Week 12, Week 24
|
|
Sleep quality
Time Frame: Week 0-24
|
German version of the questionnaire "Pittsburgh Sleep Quality Index" (PSQI; Buysse et al., 2008)
|
Week 0-24
|
|
Emotion regulation
Time Frame: Week 0-24
|
German questionnaire "Fragebogen zur Erhebung der Emotionsregulation bei Erwachsenen" (FEEL-E; Grob et al., 2014)
|
Week 0-24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease processing, acceptance & coping
Time Frame: Week 0, Week 6, Week 12, Week 24
|
German questionnaire "Freiburger Fragebogen zur Krankheitsverarbeitung" (FKV-LIS-SE; Muthny, 1989)
|
Week 0, Week 6, Week 12, Week 24
|
|
Anxiety & depression
Time Frame: Week 0, Week 6, Week 12, Week 24
|
German version of the questionnaire "Hospital Anxiety and Depression Scale" (HADS; Herrmann et al., 1995; Herrmann-Lingen et al., 2011; Zigmond & Snaith, 1983)
|
Week 0, Week 6, Week 12, Week 24
|
|
Health-related quality of life (HRQOL)
Time Frame: Week 0-24
|
German version of the questionnaire "Short Form 12 Health Survey" (SF-12; Morfeld et al., 2012)
|
Week 0-24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dagmar A Schmid, Dr. med, Klinik für Psychosomatik und Konsiliarpsychiatrie, Kantonsspital St.Gallen
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-01324
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.